Gene: CRPPA
Official Full Name: CDP-L-ribitol pyrophosphorylase Aprovided by HGNC
Gene Summary: This gene encodes a 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase-like protein. Mutations in this gene are the cause of Walker-Warburg syndrome. Alternate splicing results in multiple transcript variants. [provided by RefSeq, May 2012]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO18527 | CRPPA Knockout cell line (HCT 116) | Human | CRPPA | 1:2~1:4 | Negative | Online Inquiry |
KO18528 | CRPPA Knockout cell line (HEK293) | Human | CRPPA | 1:3~1:6 | Negative | Online Inquiry |
KO18529 | CRPPA Knockout cell line (A549) | Human | CRPPA | 1:3~1:4 | Negative | Online Inquiry |
CRPPA Gene Knockout Cell Lines are sophisticated biological tools designed to facilitate the study of gene function by enabling researchers to create cell lines lacking the expression of specific genes, particularly the CRPPA gene (C-Reactive Protein Precursor Alpha). These cell lines allow for an in-depth investigation of the genetic and molecular pathways involving CRPPA, contributing valuable insights into its role in inflammation and immune response.
The key mechanism underlying these knockout cell lines is the use of targeted gene editing technologies, such as CRISPR-Cas9, which effectively disrupt the CRPPA gene’s coding sequence. This targeted approach results in a loss of protein function, thereby allowing scientists to monitor changes in cellular behavior, gene expression, and phenotypic characteristics when CRPPA is absent. By employing these cell lines, researchers can elucidate the biological significance of CRPPA in various physiological and pathological contexts.
The scientific importance of CRPPA gene knockout cell lines cannot be overstated; they serve as invaluable tools in translational research aimed at understanding chronic inflammatory diseases, autoimmune disorders, and potential therapeutic targets. Their applications extend into drug development and testing, offering a controlled experimental environment where the implications of CRPPA disruption can be systematically studied.
One of the distinct advantages of our CRPPA Gene Knockout Cell Lines over alternative products is their high specificity and efficiency in gene disruption, alongside validated performance metrics that guarantee reproducibility in experimental settings. Additionally, these cell lines are extensively characterized to ensure consistent results, making them reliable resources for researchers aiming to draw meaningful conclusions.
Our product offers significant value to researchers and clinicians alike, as it provides a robust platform for advancing knowledge in immunology, disease pathology, and therapeutic intervention strategies. The deep insights gleaned from studies using these cell lines can lead to innovative treatment modalities and improved patient outcomes.
Our company prides itself on its expertise in genetic engineering and biological product development, ensuring that our offerings meet the highest standards of quality and scientific rigor. By choosing our CRPPA Gene Knockout Cell Lines, you are equipping yourself with a state-of-the-art tool to drive your research forward and make groundbreaking discoveries in the life sciences.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.